Topic
What to know about Foundayo, Lilly's daily GLP-1 pill?
Foundayo, Lilly's daily GLP-1 pill: approval status, results, side effects and cost, all from sourced references.
Foundayo FAQ: 31 Common Questions About Orforglipron AnsweredFoundayo is Eli Lilly's once-daily GLP-1 pill for weight loss, FDA-approved April 1, 2026. Trial participants on the highest dose lost 12.4% of body weight; self-pay starts at $149 per month, $25 with commercial coverage.Foundayo Results: What the Clinical Trials Actually ShowIn the 72-week ATTAIN-1 trial, people on the highest dose of Foundayo (orforglipron) lost an average of 12.4% of body weight (27.3 lbs) by the efficacy estimand, versus 0.9% on placebo. Lower figures like 11.2% come from the treatment-regimen estimand, not a different result.Foundayo Side Effects: Common, Serious, and What to Watch ForFoundayo's most common side effects are nausea, constipation, diarrhea, vomiting, fatigue, and hair loss, all reported in 5% or more of trial patients. Serious risks include pancreatitis and a boxed warning on thyroid tumors. In ATTAIN-1, 5.3 to 10.3% stopped due to side effects vs 2.7% on placebo.Foundayo vs Wegovy Pill: How the Two Oral GLP-1s CompareFoundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg) are both once-daily weight-loss tablets, but no head-to-head weight trial exists. The key differences are dosing rules, approved uses, and cost.How Much Does Foundayo Cost? Prices With and Without InsuranceFoundayo (orforglipron) costs $149–$299 per month self-pay, as little as $25 per fill with commercial insurance that covers it, and $50 per month for eligible Medicare Part D patients through the GLP-1 Bridge. Lilly's list price is $649.00 per 30-day supply.What Is Foundayo? The New Once-Daily GLP-1 Weight-Loss PillFoundayo is Eli Lilly's brand name for orforglipron, a once-daily GLP-1 pill the FDA approved on April 1, 2026 for weight management. In trials, people who stayed on the highest dose lost an average of 12.4% of body weight (27.3 lbs) at 72 weeks.